Consider issuing circular on side-effects of drug: HC to FDA

Image
Press Trust of India Mumbai
Last Updated : Sep 01 2013 | 3:25 PM IST
Bombay High Court has asked the Food and Drug Administration (FDA) to consider issuing a circular for doctors pointing out the side effects of the drug 'thalidomide', which is prescribed to pregnant women for nausea and morning sickness.
The suggestion was made by the division bench of Chief Justice Mohit Shah and Justice MS Sanklecha while hearing a petition filed by one Rajdeep Deshmukh, claiming that the drug causes congenital deformity.
According to the petitioner, who himself suffers from the disorder which has affected two fingers each on both his hands, use of the drug is widely known to cause phocomelia (malformation of limbs).
"The petitioner's mother was prescribed the drug for nausea and to alleviate morning sickness. But the drug was banned earlier due to its severe side effects.
"However, the doctor treating her prescribed the drug unaware about its consequences," the petition states.
While hearing the petition earlier this week, high court had directed that FDA be included as a respondent in the matter with a suggestion for it to consider issuing a circular regarding the drug for gynaecologists and obstetricians.
The matter has been posted for a hearing on Sept. 6.
Deshmukh had approached high court after the Special Medical Board certified that he was unfit for Health Science Courses.
"We are of the view that it is a fit case for directing the Director of Medical Examination and Research to send the petitioner for another... Disability test to a special medical board at JJ Hospital within a week," high court directed.
It has asked the report for the above test to be submitted by Sept. 6.
Deshmukh's advocate Pooja Thorat argued that the functional capacity of his upper limb was very strong and he can carry out all routine activities without any difficulty.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 01 2013 | 3:25 PM IST

Next Story